Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 1/20 | 0.55 |
| ▸ | CA12 | O43570 | 6/20 | 0.48 |
| ▸ | CA1 | P00915 | 6/20 | 0.48 |
| ▸ | CA2 | P00918 | 6/20 | 0.48 |
| ▸ | CA4 | P22748 | 3/20 | 0.48 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.48 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | LPAR1 | Q92633 | 3/20 | 0.47 |
| ▸ | LPAR5 | Q9H1C0 | 2/20 | 0.47 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.46 |
| ▸ | LIMK2 | P53671 | 1/20 | 0.46 |
| ▸ | NAMPT | P43490 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6541428 | 0.85 | L3MBTL1 (0.58) | CA12CA1CA2CA4TAS2R14 | |
| SCHEMBL6540868 | 0.84 | LPAR1 (0.55) | CA12CA1CA2CA4LPAR1 | |
| SCHEMBL6540792 | 0.83 | CA12 (0.55) | CA12CA1CA2CA4RCE1 | |
| SCHEMBL6540559 | 0.80 | LPAR1 (0.56) | CA12CA1CA2CA4RCE1 | |
| SCHEMBL6798502 | 0.79 | CA12 (0.55) | CA12CA1CA2CA4RCE1 | |
| SCHEMBL6540809 | 0.78 | CA12 (0.42) | CA12CA1CA2CA4RCE1 | |
| SCHEMBL6540096 | 0.77 | LPAR1 (0.54) | CA12CA1CA2CA4GAA | |
| SCHEMBL6540059 | 0.76 | L3MBTL1 (0.49) | RCE1L3MBTL1LPAR1LPAR5 | |
| SCHEMBL6540116 | 0.76 | TAS2R14 (0.52) | HTR6TAS2R14ALDH1A1LPAR1LPAR5 | |
| SCHEMBL6540329 | 0.76 | TAS2R14 (0.54) | CA12CA1CA2CA4RCE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040138462-A1 | Aminoalcohol derivatives | ASTELLAS PHARMA INC. (JP) | 2004-07-15 | — | — | US | disclosed |
| EP-1389185-A2 | AMINOALCOHOL DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-02-18 | — | — | EP | disclosed |
| WO-2002094770-A2 | AMINOALCOHOL DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-11-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138462-A1 | Aminoalcohol derivatives | BPHL, FANCD2, HRH2 | HTR6 522/4885CA12 4283/4885CA1 4181/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.